81 related articles for article (PubMed ID: 22864906)
1. Study of the involvement of pancreastatin in the physiopathology of diabetes mellitus associated with nonsecreting pituitary adenomas.
Prévost G; Eas F; Duparc C; Cauliez B; Laquérrière A; Fréger P; Lefebvre H; Kuhn JM
Horm Metab Res; 2012 Oct; 44(11):861-5. PubMed ID: 22864906
[TBL] [Abstract][Full Text] [Related]
2. Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression.
Jin L; Scheithauer BW; Young WF; Davis DH; Klee GG; Lloyd RV
Am J Pathol; 1996 Jun; 148(6):2057-66. PubMed ID: 8669489
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the chromogranin A post-translational cleavage product pancreastatin and the prohormone convertases PC2 and PC3 in normal and neoplastic human pituitaries.
Lloyd RV; Jin L; Qian X; Scheithauer BW; Young WF; Davis DH
Am J Pathol; 1995 May; 146(5):1188-98. PubMed ID: 7747813
[TBL] [Abstract][Full Text] [Related]
4. Pancreastatin plasma levels in patients with primary hyperparathyroidism.
Bergenfelz A; Luts L; Jensen TB; Sundler F
World J Surg; 2000 Dec; 24(12):1579-83. PubMed ID: 11193727
[TBL] [Abstract][Full Text] [Related]
5. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients.
Syversen U; Mignon M; Bonfils S; Kristensen A; Waldum HL
Acta Oncol; 1993; 32(2):161-5. PubMed ID: 8323758
[TBL] [Abstract][Full Text] [Related]
7. Increased plasma pancreastatin-like immunoreactivity levels in non-obese patients with essential hypertension.
Sánchez-Margalet V; Valle M; Lobón JA; Maldonado A; Escobar-Jimenez F; Oliván J; Pérez-Cano R; Goberna R
J Hypertens; 1995 Feb; 13(2):251-8. PubMed ID: 7615956
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
9. Pancreastatin distribution and plasma levels in the pig.
Bretherton-Watt D; Ghatei MA; Bishop AE; Facer P; Fahey M; Hedges M; Williams G; Valentino KL; Tatemoto K; Roth K
Peptides; 1988; 9(5):1005-14. PubMed ID: 3244555
[TBL] [Abstract][Full Text] [Related]
10. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
[TBL] [Abstract][Full Text] [Related]
11. Increased plasma pancreastatin-like levels in gestational diabetes: correlation with catecholamine levels.
Sánchez-Margalet V; Lobón JA; González A; Fernández-Soto ML; Escobar-Jiménez F; Goberna R
Diabetes Care; 1998 Nov; 21(11):1951-4. PubMed ID: 9802749
[TBL] [Abstract][Full Text] [Related]
12. Morphological study of clinically nonsecreting pituitary adenomas in patients under 40 years of age.
Yamada S; Kovacs K; Horvath E; Aiba T
J Neurosurg; 1991 Dec; 75(6):902-5. PubMed ID: 1941118
[TBL] [Abstract][Full Text] [Related]
13. Recognition of gonadotroph adenomas in women.
Daneshdoost L; Gennarelli TA; Bashey HM; Savino PJ; Sergott RC; Bosley TM; Snyder PJ
N Engl J Med; 1991 Feb; 324(9):589-94. PubMed ID: 1899470
[TBL] [Abstract][Full Text] [Related]
14. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
Rustagi S; Warner RR; Divino CM
J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
[TBL] [Abstract][Full Text] [Related]
15. Plasma pancreastatin-like immunoreactivity in various diseases.
Tateishi K; Funakoshi A; Wakasugi H; Iguchi H; Shinozaki H; Abe M; Funakoshi S; Tamamura H; Yajima H; Matsuoka Y
J Clin Endocrinol Metab; 1989 Dec; 69(6):1305-8. PubMed ID: 2555388
[TBL] [Abstract][Full Text] [Related]
16. Comparison of hormonal secretory behavior of gonadotroph cell adenomas in vivo and in culture.
Snyder PJ; Bashey HM; Phillips JL; Gennarelli TA
J Clin Endocrinol Metab; 1985 Dec; 61(6):1061-5. PubMed ID: 2414310
[TBL] [Abstract][Full Text] [Related]
17. Novel peptide pancreastatin: its occurrence and codistribution with chromogranin A in the central nervous system of the pig.
Kar S; Bretherton-Watt D; Gibson SJ; Steel JH; Gentleman SM; Roberts GW; Valentino K; Tatemoto K; Ghatei MA; Bloom SR
J Comp Neurol; 1989 Oct; 288(4):627-39. PubMed ID: 2808753
[TBL] [Abstract][Full Text] [Related]
18. Normal pancreastatin-like and increased post-glucose insulin levels in young offspring of insulin-resistant non-obese essential hypertensive patients.
Sánchez-Margalet V; Ramos E; Mateo J; Oliván J; Pérez-Cano R; Goberna R
J Endocrinol; 1997 May; 153(2):313-8. PubMed ID: 9166122
[TBL] [Abstract][Full Text] [Related]
19. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Korbonits M; Jacobs RA; Aylwin SJ; Burrin JM; Dahia PL; Monson JP; Honegger J; Fahlbush R; Trainer PJ; Chew SL; Besser GM; Grossman AB
J Clin Endocrinol Metab; 1998 Oct; 83(10):3624-30. PubMed ID: 9768675
[TBL] [Abstract][Full Text] [Related]
20. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior.
O'Dorisio TM; Krutzik SR; Woltering EA; Lindholm E; Joseph S; Gandolfi AE; Wang YZ; Boudreaux JP; Vinik AI; Go VL; Howe JR; Halfdanarson T; O'Dorisio MS; Mamikunian G
Pancreas; 2010 Jul; 39(5):611-6. PubMed ID: 20124939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
